RSV vaccine study for healthy women
Treatments studied
Part of Infections clinical trials.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 49.
- You are generally healthy (no serious ongoing illnesses).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
- You have not had RSV infection or an RSV vaccine in the past 6 months.
- You have not received certain vaccines, blood products, or investigational drugs recently.
- You do not have a weak immune system, active cancer, or certain chronic conditions like heart, lung, liver, or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.